Participated · Series C · Jan 2024

DPM is a high-end medical device and innovative medical technology provider specializing in intraoperative precise optical molecular imaging products and technologies. The company develops and provides comprehensive intraoperative molecular imaging navigation solutions and services. Its product focus centers on surgical optical molecular imaging to guide procedures. The article reports that DPM recently completed a financing round exceeding RMB 200 million. The financing is described as a C round. Participating investors named in the report include Daohe Zhiyi, Huiding Investment, and Yunqi Investment, with Huaxing Capital serving as exclusive financial advisor.

Led · Series B · May 2022

InxMed is a clinical-stage biotechnology company based in Nanjing that develops therapies targeting the stromal microenvironment to overcome solid tumor resistance and metastasis. Founded at the end of 2018 and led by CEO Dr. Zaiqi Wang, the company focuses particularly on addressing anti‑PD‑1/PD‑L1 treatment resistance. Its lead asset, IN10018, is a potent and highly selective ATP‑competitive FAK inhibitor for which InxMed holds exclusive global development and commercial rights. IN10018 received FDA fast track designation in August 2021 and a breakthrough designation from China’s NMPA for the treatment of platinum‑resistant ovarian cancer. InxMed plans to use the $15M raised in a Series B+ to accelerate ongoing clinical trials in the US and China, initiate pivotal trials in the second half year, advance additional stroma‑targeting programs into clinics, and strengthen R&D capabilities in Nanjing. The company has established partnerships with multinational pharmaceutical companies including Merck, Roche and Boehringer Ingelheim and intends to disclose more IN10018 data at ASCO in June 2022. InxMed Co., Ltd is a clinical-stage biotechnology company based in Nanjing, China, focused on therapies that target the stromal microenvironment and drug resistance in hard-to-treat solid tumors. Its lead asset, IN10018, is a potent, selective ATP-competitive focal adhesion kinase (FAK) small-molecule inhibitor with ongoing trials in NRAS mutant metastatic melanoma, platinum-resistant ovarian cancer, and triple-negative breast cancer. The U.S. Food and Drug Administration granted Fast Track designation to IN10018 for platinum-resistant ovarian cancer in August 2021 based on preliminary efficacy. The company says it will use the $50M Series B proceeds to accelerate IN10018 clinical trials in both the U.S. and China, including initiation of pivotal trials, and to advance additional stroma-targeting programs into the clinic this year. InxMed has built translational medicine and clinical development teams across Shanghai, Beijing, Nanjing, the United States, Canada, and Australia, and has partnerships with Merck, Roche, and Boehringer Ingelheim. The company is led by founder and CEO Dr. Zaiqi Wang and will strengthen R&D capabilities in Nanjing with the new funding. InxMed is a Nanjing-based biotech focused on developing FAK inhibitors. The company is advancing a program toward Phase I development of a FAK inhibitor. Nearly a year after securing its first IND approval, InxMed raised new capital to support clinical progress. The company completed a ¥130 million (about $19 million) Series A+ financing. Proceeds from the raise are intended to fund the Phase I FAK inhibitor program. Zaiqi Wang is named as CEO.

Participated · Series A · Dec 2021

Cargene Biopharma is a preclinical-stage biopharmaceutical company developing oligonucleotide therapeutics, including highly potent, specific and stable siRNAs, for cardiovascular, fibrotic and pulmonary indications. Its proprietary OSCAR™ algorithm and SMoP™ pharmacophore design platforms are used together to rapidly design siRNAs, with initial programs focused on cardiovascular disease and non-alcoholic steatohepatitis (NASH). The company has exclusively in-licensed regenerative medicine-related technology from A*STAR aimed at reducing liver fibrosis and has demonstrated effects in acute and chronic liver disease models and human cell assays. Cargene is also developing targeted delivery technologies for oligonucleotides to multiple organs and novel nucleosides to boost siRNA efficacy. It operates in Singapore, the USA and China and is supported by a scientific board including Professors Harvey Lodish, Roger Foo, Kausik Ray and Torsten Wuestefeld. The company intends to use the recent funding to advance its lead asset toward an investigational new drug (IND) application and accelerate broader technology development.

Led · Series C · May 2021

Oculis is a helvetico-Icelandic biopharmaceutical company focused on creating innovative treatments for eye and neurological disorders. The firm is legally based in Zug with its operational headquarters in Lausanne. Its pipeline of ophthalmic therapies has attracted strong investor interest, reflected in two capital increases exceeding $100 million within a year. Management states that the newly secured funds will accelerate the clinical development of its drug candidates. The company positions itself as a leader in addressing unmet medical needs in ophthalmology through novel therapeutic approaches. Financially, Oculis has now raised at least $220 million across its last two rounds, underscoring sustained investor confidence. No revenue or user metrics were disclosed in the available article excerpt.